Harmony Biosciences (HRMY) Appoints Jeffrey M. Dayno as President and CEO

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Jeffrey M. Dayno, M.D., has been appointed President and Chief Executive Officer by the Company's Board of Directors and has been elected to join as a member of the Board.

Dr. Dayno joined Harmony as Chief Medical Officer and Executive Vice President when the company was founded in 2017 and has been serving as Interim President and CEO since January 6, 2023.

Harmony Board Chairman, Jeff Aronin, noted that Dr. Dayno, a nationally recognized neuroscience expert, has been a valuable member of the Company's inaugural executive management team since 2017. He played a critical role in the FDA approval of Harmony's key asset, WAKIX® (pitolisant), and helped to shape commercial strategy.

"Dr. Dayno has been an influential leader since day one. The Board unanimously appointed him President and CEO because it firmly believes in his vision for ongoing strong growth in critical areas of the business," said Mr. Aronin. "We believe he will continue to expand the WAKIX franchise in narcolepsy, pursue new indications for patients and advance the pipeline of new assets. That is a clear path to short- and long-term value for Harmony's shareholders."

With the appointment, Mr. Aronin returns to serving as non-executive Chairman of the Board. Dr. Dayno expressed appreciation for the Board's confidence in his leadership.

"After 12 years as a practicing neurologist taking care of patients, followed by 25 years in the industry touching every aspect of the business, I have seen the impact that developing and delivering innovative treatments can have on patients and their families. I am honored that the Board has asked me to lead the company forward in our next phase of growth," said Dr. Dayno. "We are confident in WAKIX being a potential $1 billion-plus narcolepsy opportunity, with the potential to contribute up to an additional $1 billion if approved in idiopathic hypersomnia and other current lifecycle management programs. I am passionate about leading the company forward and will focus on advancing our lifecycle management programs and acquiring new assets to build out our pipeline."

You May Also Be Interested In

• RedHill Biopharma (RDHL) Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
• EBR Systems (EBR) receives FDA approval for WiSE System
• Coeptis (COEP) partners with NexGenAI and Ishvara to launch tech hub in India